Literature summary for 3.4.23.15 extracted from

Imanishi, T.; Tsujioka, H.; Ikejima, H.; Kuroi, A.; Takarada, S.; Kitabata, H.; Tanimoto, T.; Muragaki, Y.; Mochizuki, S.; Goto, M.; Yoshida, K.; Akasaka, T.
Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes (2008), Hypertension, 52, 563-572.

Search for more literature for 3.4.23.15

Application

Application	Comment	Organism
pharmacology	treatment of Watanabe heritable hyperlipidemic rabbits with aliskiren or aliskiren plus valsartan leads to greater increases in plasma nitric oxide concentration in response to intra-aortic acetylcholine infusion than in control. Aliskiren plus valsartan treatment increases acetylcholine-induced nitric oxide by 6.2 nmol/l, which is significantly higher than with either aliskiren or valsartan alone. Vascular superoxide and peroxynitrite levels are both significantly higher in controls and significantly lower in the aliskiren plus valsartan group than in the aliskiren or valsartan group	Oryctolagus cuniculus

Inhibitors

Inhibitors	Comment	Organism	Structure
aliskiren	treatment of Watanabe heritable hyperlipidemic rabbits with aliskiren or aliskiren plus valsartan leads to greater increases in plasma nitric oxide concentration in response to intra-aortic acetylcholine infusion than in control. Aliskiren plus valsartan treatment increases acetylcholine-induced nitric oxide by 6.2 nmol/l, which is significantly higher than with either aliskiren or valsartan alone. Vascular superoxide and peroxynitrite levels are both significantly higher in controls and significantly lower in the aliskiren plus valsartan group than in the aliskiren or valsartan group	Oryctolagus cuniculus

Organism

Organism	UniProt	Comment	Textmining
Oryctolagus cuniculus	-	Watanabe heritable hyperlipidemic rabbit	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)